Early urate-lowering therapy in gouty arthritis with acute flares: a double-blind placebo controlled clinical trial. [PDF]
Eur J Med Res, 2023 Background Gouty arthritis (GA) is a chronic systemic disease with recurrent acute monoarthritis. In a previous study, a higher incidence of acute flares was observed during the initial marked decrease in serum urate level. Our study evaluated the effect
Yang DH, Chen HC, Wei JC.
europepmc +4 more sources
Determinants of Achieving Serum Urate Goal with Treat-to-Target Urate-Lowering Therapy in Gout. [PDF]
Arthritis Rheumatol, 2023 Using trial data comparing treat‐to‐target allopurinol and febuxostat in gout, we examined participant characteristics associated with serum urate (SU) goal achievement.
Helget LN +13 more
europepmc +4 more sources
Lowering Serum Urate With
Arthritis & Rheumatology, 2023 Gout is associated with a higher risk of fracture; however, findings on the associations of hyperuricemia and urate‐lowering therapy (ULT) with the risk of fracture have been inconsistent.
Jie Wei +8 more
openalex +2 more sources
Moving urate-lowering therapy in gout beyond guideline recommendations
Seminars in Arthritis and RheumatismThe 'treat-to target serum urate strategy' when using urate-lowering therapy has been recommended by most specialist rheumatology societies for many years. An alternative "treat-to-avoid-symptoms" in gout has been suggested, albeit without a clear definition of what this means and how it might be implemented in clinical trials or clinical practice ...
Lisa K Stamp, Nicola Dalbeth
openaire +3 more sources
Principles of urate-lowering therapy: eight steps to success
Современная ревматология, 2023 Treatment of such a serious systemic disease as gout is often carried out incorrectly, despite the presence of a large number of recommendations and drugs.
O. V. Zhelyabina +2 more
doaj +2 more sources
Urate lowering therapy in primary care: rheum for improvement [PDF]
Exploration of Musculoskeletal DiseasesPrimary care physicians (PCPs) play a critical role in the management of gout worldwide. However, significant gaps in gout care persist, underscoring the need for improved approaches to its management.
Emilie Schurenberg +2 more
doaj +2 more sources
Urate-Lowering Therapy Inhibits Thoracic Aortic Aneurysm and Dissection Formation in Mice [PDF]
Arteriosclerosis, Thrombosis and Vascular Biology, 2023 Background: Thoracic aortic aneurysm and dissection (TAAD) is a highly lethal vascular disease without effective drug therapy. Whether elevated serum concentrations of uric acid are involved in TAAD development remains unclear.
Yang Liu +17 more
openalex +2 more sources
Oral Urate-Lowering Therapy Use and Efficacy Following Pegloticase Treatment: Findings from a Rheumatology Network Database. [PDF]
Rheumatol TherPadnick-Silver L +5 more
europepmc +3 more sources
I83. Population Use of Urate-Lowering Therapy [PDF]
Rheumatology, 2015 Michael Doherty
openalex +2 more sources
Pacific community's perceptions on how to improve uptake of urate-lowering therapy for Pacific gout patients. [PDF]
Int J Equity HealthThis study aims to explore the views of Pacific people on how to improve the management of urate-lowering therapy among Pacific gout patients in South Auckland. The study used the Fa’afaletui model to explore the views on gout management across different
Ofanoa S +5 more
europepmc +2 more sources